Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy” Seren M. Gedallovich, Paul Y. Kwo Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef
Metformin in Antiviral Therapy: Evidence and Perspectives Iryna Halabitska, Pavlo Petakh, Oleh Lushchak, Iryna Kamyshna, Valentyn Oksenych, Oleksandr Kamyshnyi Viruses.2024; 16(12): 1938. CrossRef
Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct acting antiviral agents has revolutionized the treatment of hepatitis C with finite, highly effective, well-tolerated therapy and there are few populations that cannot be successfully treated now or are complicated to manage. The World Health Organization has released elimination targets in an effort to eliminate viral hepatitis and reduce dramatically the morbidity and mortality caused by both viral hepatitis. While hepatitis C is straightforward to treat, it remains problematic to eliminate on a global scale. Diagnosis of hepatitis C remains the major gap in the cascade of care and numerous screening strategies will be required to reduce this gap. While historically, treatment of hepatitis C has been centralized, decentralized approaches will be required to diagnose, evaluate, and link to care the large population of individuals worldwide with hepatitis C across low-, middle-, and high-income countries. With the introduction of multiple pangenotypic treatment options and reduced cost for these therapies, assessment and treatment for those with hepatitis C has been simplified and made more accessible worldwide. There are multiple populations for whom care models are being developed and refined, including those when inject drugs, those who are incarcerated, those who present with sexually transmitted disease including the men who have sex with men population, amongst many others. While a vaccine for hepatitis C remains elusive these efforts continue. Multiple successful elimination efforts have been reported.
Citations
Citations to this article as recorded by
Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev Сибирский научный медицинский журнал.2025; 45(1): 6. CrossRef
Current treatments and the future of nanomedicine in hepatitis C Drue Julien, Horacio Bach Nanomedicine.2025; 20(13): 1589. CrossRef
Metabolic dysfunction, cirrhosis, and HCV genotype 3a drive type 2 diabetes risk in chronic hepatitis C: a Southern Chinese cohort study Zhanyi Li, Yuyu Ye, Yeqiong Zhang, Wenxiong Xu, Ying Liu BMC Gastroenterology.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review) N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev Cell and Tissue Biology.2025; 19(6): 525. CrossRef
Impact of a Simplified Care Model on Direct-acting Antiviral Treatment for Hepatitis C Virus-positive People in Addiction Care: A Retrospective Review of the trueNorth Medical Centres Database Chris Cavacuiti, Roger Gaertner, Veeral Gandhi Canadian Journal of Addiction.2024; 15(2): 50. CrossRef
State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France Marine Chlebus, Laurence Boyer, Sébastien Doerper, Tristan Hergot, Mihayl Varbanov Venereology.2024; 3(2): 63. CrossRef
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review Malik Sallam, Roaa Khalil Microorganisms.2024; 12(6): 1035. CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease” Won Sohn, Yong-Han Paik Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Case report: Chronic hepatitis C with anti-HCV positive and serum HCV RNA negative Huihui Lu, Wen Deng, Yao Lu, Lu Zhang, Yao Xie, Minghui Li Gastroenterology & Endoscopy.2023; 1(2): 120. CrossRef
Management of in- and out-of-hospital screening for hepatitis C Jing Zhou, Fa-Da Wang, Lan-Qing Li, En-Qiang Chen Frontiers in Public Health.2023;[Epub] CrossRef
Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong Clinical and Molecular Hepatology.2023; 29(2): 496. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
Liver transplantation for malignant liver tumors Richard X. Sousa Da Silva, Beat Muellhaupt, Philipp Dutkowski, Pierre-Alain Clavien iLIVER.2022; 1(1): 3. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun Clinical and Molecular Hepatology.2022; 28(4): 876. CrossRef
How to Optimize the Care Cascade of Hepatitis C Virus Infection Beom Kyung Kim Gut and Liver.2022; 16(6): 809. CrossRef
Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications Eyal Klang, Shelly Soffer, Lee Alper, Orit Shimon, Yiftach Barash, Yana Davidov, Mariya Likhter, Oranit Cohen‐Ezra, Gil Ben Yakov, Ziv Ben‐Ari Health Science Reports.2022;[Epub] CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler Biomedicines.2022; 10(12): 3152. CrossRef
First
Prev
